Press Releases
10.03.2010
Max Planck Innovation licenses innovative sampling system to bbi-biotech
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, is concluding two exclusive licensing agreements for a liquid sampling system with bbi-biotech GmbH, an innovative biotechnology company. The technology, developed at the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, provides a sterile and economical way of taking samples for bioprocess analysis. continue
12.11.2009
Max Planck Innovation awards license to Solexel for an innovative method to develop thin-film solar cells
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany’s leading basic research organization, has signed a co-exclusive license agreement for its Porous-Silicon-Process (PSI process) technology with Solexel, Inc., a company focusing on the development and commercialisation of high-efficiency thin-film photovoltaic arrays and solar modules. continue
13.10.2009
Max Planck Innovation grants rights for developing new nanoscopic method to Leica Microsystems
Max Planck Innovation, the technology transfer organization of the Max Planck Society, grants Leica Microsystems, Wetzlar, an exclusive license for implementing the latest generation of optical microscopes with a resolution far below the diffraction limit (nanoscopes). This innovative optical nanoscopy, named GSDIM (ground state depletion microscopy followed by individual molecule return), achieves image resolutions in the nanometer range – even in conventional wide field microscopes. GSDIM was ... continue
18.08.2009
Max Planck Innovation announces an exclusive licensing agreement with PerkinElmer for its Silicon Photomultiplier (SiPM) Technology
Max Planck Innovation, the technology transfer organization of the Max Planck Society, has entered into an exclusive licensing agreement with PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, for its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology. continue
14.05.2009
Max Planck Innovation and LSP to launch DDC Ventures, a new pharmaceutical Venture Capital Fund
Max Planck Innovation GmbH, the technology transfer arm of Germany’s Max Planck Society, has today announced that LSP, a leading European venture fund manager, has been appointed to manage a new EUR 100 million venture capital fund. The fund will make investments into pharmaceutical projects primarily originating from the life science institutes of the Max Planck Society, one of the world’s most renowned research organisations. continue
30.09.2008
Max Planck Innovation's Drug Discovery and Development Center Wins BioPharma Strategy Competition
Project will receive €20 million in funding from the BMBF - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society (MPG), announces today that its concept for a novel Drug Discovery and Development Center (DDC) will receive €20 million in funding from the German Ministry of Education and Research (BMBF) through its initiative "BioPharma - The strategy competition for medicine of the future". The DDC was selected as one of three winners that were presented ... continue
21.07.2008
Dafra Pharma R&D has been awarded an exclusive licence from the Max Planck Society to develop a drug against leishmaniasis
Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research company belonging to Dafra Pharma International, signed a license agreement today for the development and commercialisation of a new drug against leishmaniasis. continue
17.06.2008
Lead Discovery Center Starts Operations
Supporting the development of novel medicines in Germany - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today the opening of its new subsidiary, the Lead Discovery Center GmbH (LDC). It will be based in Dortmund, Germany, and intends to employ a staff of 15-20 experienced drug discovery scientists, project managers, and technical assistants by the end of 2008. continue
12.06.2008
Max Planck Innovation Receives IPTEC Award for Excellence in Technology Transfer
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, was honored for outstanding achievement in developing technology transfer and licensing in the public sector. The award was presented yesterday, June 11, during the third International Marketplace and Conference for Technology Transfer Professionals (IPTEC) in Frankfurt. continue
03.03.2008
Max Planck Innovation's Drug Discovery Center Selected for Final Round of the BioPharma Strategy Competition
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today that its concept for a novel Drug Discovery Center (DDC) has reached the final round of the "BioPharma - strategy competition for medicine of the future", a support program of the German Ministry of Education and Research (BMBF). continue
12.12.2007
Max Planck Innovation and AmVac Enter Partnership for the Development of Novel Vaccines
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, has closed a license agreement with Swiss AmVac AG, a biopharmaceutical company focused on the development and commercialization of innovative vaccines. Under the terms of the agreement, AmVac obtains the exclusive right to further develop and commercialize a technology that enables the design and production of a new class of vaccines with improved safety and efficacy. In return, Max Planck Innovation receives ... continue
29.10.2007
Max Planck Innovation and FuMA-Tech sign exclusive licencing agreement for novel fuel cell technology
New membrane material solves crucial problem for methanol-based fuel cells continue
01.08.2007
Alnylam Receives Allowance from European Patent Office for Tuschl II Patent, Exclusively Licensed from Max Planck Society
Tuschl II Patent in Europe Covers Compositions, Methods, and Uses of Small Interfering RNAs in World's Second Largest Pharmaceutical Market / Tuschl II Patent also Granted in Australia continue
21.05.2007
Max Planck Innovation Concludes Licensing Agreement for Technology Providing Unlimited Resolution in Microscopy
Overcoming Abbe's law in light microscopy continue
15.02.2007
KeyNeurotek AG and Max Planck Society sign licence and cooperation agreement for drug development
06.02.2007
Max Planck Innovation Concludes Diagnostic microRNA Licensing Agreement
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany's leading basic research organization, has signed a co-exclusive license agreement with Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products. Under the terms of the agreement, Stratagene has been granted rights to patents covering more than 150 human microRNA sequences for use in diagnostic applications. continue
23.10.2006
From Garching Innovation to Max Planck Innovation
The technology transfer company of the Max Planck Society will operate under the new name Max Planck Innovation. continue
21.08.2006
Max Planck Research leads to EU approval for cancer medication
The European Union has now approved SUTENT®. The basic mechanism behind the medication was discovered in the 1990s by Max Planck scientists, led by Prof. Axel Ullrich. The resulting patents were licensed by Garching Innovation GmbH, the technology transfer organisation of the Max Planck Society. continue
News alert
Do you want to receive our newsletter and press releases?
Subscribe here
Media contact
Markus Berninger
Phone: (089) 290919-30